| Literature DB >> 26932392 |
C Ren1, C McGrath1, L Jin1, C Zhang1, Y Yang1.
Abstract
BACKGROUND AND OBJECTIVES: Although low-level laser therapy (LLLT) has been demonstrated to have a biomodulatory effect on periodontal tissue, no systematic review has exclusively addressed its effectiveness as an adjunct to non-surgical periodontal treatment. This study aimed to evaluate whether an additional benefit exists for the application of LLLT compared with scaling and root planing (SRP) alone.Entities:
Keywords: chronic periodontitis; low-level laser therapy; non-surgical periodontal treatment; systematic review
Mesh:
Year: 2016 PMID: 26932392 PMCID: PMC5297978 DOI: 10.1111/jre.12361
Source DB: PubMed Journal: J Periodontal Res ISSN: 0022-3484 Impact factor: 4.419
Figure 1PRISMA flow diagram of the study inclusion process.
Characteristics of included studies
| Study ID | No. of subjects (M/F), target teeth and sites (anterior/posterior) | Age in mean ± SD (range) and Country | Inclusion criteria for CP | No. of smokers (M/F) | Study design | Treatment | Outcome measures | Evaluation interval and follow‐up |
|---|---|---|---|---|---|---|---|---|
| Angelov |
I: 60 CP subjects (32/28) |
I: 48.9 (35–70) | Moderate or severe CP | Smokers not included | RCT (parallel) |
Ia: SRP |
Clinical parameters: PI, GI, SBI | Baseline and after treatment (10 d) |
| Aykol |
36 CP subjects (22/14) |
I: 43.56 ± 6.70 |
1. moderate to advanced CP |
18 smokers criteria: ≥10 cigarettes per day | RCT (parallel) |
I: SRP+LLLT |
Clinical parameters: PI, SBI, PPD, CAL | Baseline, 1, 3 and 6 mo after treatment (6 mo) |
| Calderín |
27 CP subjects (12/15) |
|
1. moderate to advanced CP | Smokers not included | RCT (parallel) |
Ia: SRP+ single LLLT | Clinical parameters: FMPS, FMBS, PPD, CAL biochemical markers: IL‐1β,TNF‐α, RANKL and OPG in GCF | Baseline, 4 and 8 wk after treatment (2 mo) |
| Lai |
14 CP subjects (1/13) |
43.6 (33–57) |
1. moderate to advanced CP | Smokers not included | RCT (split‐mouth) |
I: SRP+LLLT | Clinical parameters: PL, PPD, PAL, Rec, BOP alveolar bone change: periapical radiographs (DSR) biochemical markers: GCF volume |
Clinical parameters: baseline, 3, 6, 9, and 12 mo after treatment |
| Makhlouf |
16 CP subjects (4/12) |
(22–50) |
1. CP | Smokers not included | RCT (split‐mouth) |
I: SRP + LLLT | Clinical parameters: GI, PPD biochemical markers: IL‐1β in GCF bone density: intraoral radiographs | Clinical parameters and biochemical markers: baseline, 5 wk, 3 and 6 mo bone density: baseline, 6 and 12 mo (12 mo) |
| Qadri |
17 CP subjects (7/10) |
53 (35–70) |
1. moderate CP | 5 smokers | RCT (split‐mouth) |
I: SRP+ LLLT | Clinical parameters: PPD, GI, PI biochemical markers: GCF volume, elastase activity, IL‐1β, MMP‐8 level in GCF microbial analysis: subgingival plaque for 12 bacteria | Clinical parameters: baseline (before SRP), 1 wk after last LLLT; biochemical and microbial sampling: baseline (1 wk after SRP), 1 wk after last LLLT (2 mo) |
| Ribeiro |
10 CP subjects |
(15–35) |
1. CP | Smokers not included | RCT (split‐mouth) |
I: SRP+ LLLT | Clinical parameters: PPD, CAL, GI, pain level: VAS | Clinical parameters: baseline and 48 h after treatment, VAS: immediately after SRP (2 d) |
b‐FGF, basic‐fibroblast growth factor levels, IL‐1β, interleukin‐1β; BOP, bleeding on probing; C, control group; CAL, clinical attachment level; CP, chronic periodontitis; DSR, digital subtraction radiography; F, female; FMBS, full‐mouth bleeding score; FMPS, full‐mouth plaque score; GCF, gingival crevicular fluid; GI, gingival index; GR, gingival recession; I, intervention group; IL‐1α, interleukin‐1α; M, male; MMP‐1, matrix metalloproteinase‐1; MMP‐8, matrix metalloproteinase‐8; MMP‐9, matrix metalloproteinase‐9; OPG, osteoprotegerin; P, placebo group; PAL, probing attachment level; PBI, papillary bleeding index; PI, plaque index; PL, supragingival plaque; PPD, probing pocket depth; RANKL, receptor activator of nuclear factor κΒ ligand; Rec, change in recession; SBI, sulcus bleeding index; TGF‐β1, transforming growth factor‐β1; TIMP‐1, tissue inhibitor matrix metalloproteinase‐1; TNF‐α, tumour necrosis factor‐α; VAS, visual analogue scale.
The parameter and regimen of diode laser applied in included studies
| Study ID | Type of laser | Wavelength | Beam size | Output/energy (density) | Dosage per irradiation or tooth | Time of exposure | Method of application | Frequency of laser treatment | Accumulative dosage (dose × frequency) |
|---|---|---|---|---|---|---|---|---|---|
| Angelov, | Diode laser, continuous mode | 630–670 nm | 0.2 cm2 | 25 mW, 1.875 J/cm2 |
0.375 J/irradiation |
15 s/irradiation | Applied externally with a light contact to the gingival tissue corresponding to the treated pockets, scanning in apical‐coronal direction in all interdental spaces on both facial and lingual surfaces | 5 and 10 consecutive days after SRP (5 or 10 sessions) | 1.875 or 3.75 J/irradiation; 3.75 or 7.5 J/tooth |
| Aykol, | GaAlAs laser, continuous mode | 808 nm | 0.28 cm2 | 250 mW, 4 J/cm2 |
1–2 J/irradiation | Incisors and premolars: 10 s/irradiation Molar: 20 s/irradiation | Non‐contact with a distance of 0.5 to 1 cm | Day 1, 2, 7 after SRP (3 sessions) | 3–6 J/irradiation; 3–6 J tooth |
| Calderín, | Diode laser, continuous mode | 670 nm | NR | 200 mW |
6 J/irradiation |
30 s/irradiation | Inserted into the pocket no deeper than the probing depth, and gently moved all along the sulcus of buccal, lingual and interproximal surfaces | Single LLLT: Day 1 after SRP; Repeated LLLT: Day 1, 2, 4, 7, and 11 after SRP (1 or 5 sessions) | 6 or 30 J/irradiation; 12 or 60 J/tooth |
| Lai, | He‐Ne laser, continuous mode | 632 nm | 0.07 cm2 | 0.2 mW, 2.83 mW/cm2, 1.7 J/cm2 |
0.12 J/irradiation |
600 s/irradiation | The optical fiber was placed perpendicularly to the interdental papilla and kept in place touching the buccal gingival surfaces. | 8 sessions over the following 3 mo (8 sessions) | 0.96 J/irradiation; 0.96 J/tooth |
| Makhlouf, | GaAlAs laser, continuous mode | 830 nm |
0.03 cm2
| 100 mW, 3 W/cm2, 3 J/cm2 |
3 J/irradiation |
30 s/irradiation | The tip was positioned externally at the base of the pocket lingually and buccally in slight contact, perpendicularly to the long axis of the tooth, in a sweeping motion. | 3 sessions during the 1st and 2nd wk, followed by 2 sessions during the 3rd wk, and then once weekly during the 4th and 5th wk (10 sessions) | 30 J/irradiation; 60 J/tooth |
| Qadri, | Diode laser |
635 nm | 0.2 cm2 | 635 nm: 10 mW, 50 mW/cm2, 4.5 J/cm2; 830 nm: 70 mW, 350 mW/cm2, 8.75 J/cm2 |
Papillae: 0.9 J/irradiation apically: 1.75 J/irradiation |
635 nm: 90 s/irradiation | Gingival papillae were treated with 635 nm laser and 6 mm more apically with 830 nm laser from the buccal and lingual sides with slight contact. | Once a week for 6 wk after SRP (6 sessions) | 5.4 or 10.5 J/irradiation; 31.8 J/tooth |
| Ribeiro, | GaAlAs laser |
780 nm (analgesia) | 0.04 cm2 | Pre‐ and post‐ surgery analgesia: 70 mW, 35 J/cm2; wound healing: 35 mW, 8.8 J/cm2 |
Analgesia: 1.4 J/irradiation |
Analgesia: 20 s/irradiation (tooth) | Laser with 780 nm wavelength was punctually applied to the papillae and cervical region, to an apical point for analgesia. Laser with 660 nm wavelength was applied to the papillae and cervical region for drainage and tissue repair | Before and immediately after SRP, 24 and 48 h later (3 sessions) | Analgesia: 4.2 J/irradiation; 8.4 J/tooth; Wound healing: 1.05 J/irradiation; 1.05J/tooth |
Figure 2Risk of bias summary: review authors’ judgments about each risk of bias item for each included study.
Figure 3Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.
Meta‐analysis of LLLT's short‐term additional effects, comparison: SRP+LLLT versus SRP, outcome: clinical parameters (PI, PPD, CAL) and biochemical markers (IL‐1β) at 1 and 2 mo
| Evaluation interval | Outcome | Studies | Number of participants | Model | Test for total effect | Test for heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| MD/SMD | 95% CI |
|
|
| |||||
| 1 mo | PI |
| 68 | Fixed | −0.22 | −0.44 to 0.00 | 0.06 | 0 | 0.32 |
| PPD |
| 86 | Fixed | −0.40 | −0.64 to −0.17 | 0.0009 | 0 | 0.65 | |
| CAL |
| 54 | Fixed | −0.21 | −1.08 to 0.67 | 0.65 | 0 | 0.89 | |
| IL‐1β |
| 50 | Fixed | −0.77 | −1.35 to −0.18 | 0.01 | 0 | 0.43 | |
| 2 mo | PPD |
| 52 | Fixed | −0.28 | −0.54 to −0.03 | 0.03 | 86 | 0.009 |
MD, mean difference; SMD, standardized mean difference; CI, confidence interval; PI, plaque index; PPD, probing pocket depth; CAL, clinical attachment level; IL‐1β, Interleukin‐1β.
Intervention effect reported as SMD.
*p < 0.05, significant difference between SRP + LLLT and SRP.
Meta‐analysis of LLLT's intermediate‐term additional effects, comparison: SRP+LLLT versus SRP, outcome: clinical parameters (PI, PPD, CAL) and alveolar bone density at 3 and 6 mo
| Evaluation interval | Outcome | Studies | Number of participants | Model | Test for total effect | Test for heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| MD/SMD | 95% CI |
|
|
| |||||
| 3 mo | PI |
| 68 | Fixed | −0.03 | −0.32 to 0.26 | 0.84 | 0 | 0.69 |
| PPD |
| 96 | Fixed | −0.28 | −0.56 to 0.01 | 0.06 | 0 | 0.83 | |
| CAL |
| 64 | Fixed | 0.07 | −0.58 to 0.71 | 0.84 | 0 | 0.53 | |
| 6 mo | PI |
| 68 | Fixed | −0.08 | −0.27 to 0.10 | 0.39 | 0 | 0.69 |
| PPD |
| 96 | Fixed | −0.01 | −0.15 to 0.12 | 0.88 | 0 | 0.74 | |
| CAL |
| 64 | Fixed | 0.04 | −0.62 to 0.69 | 0.91 | 0 | 0.88 | |
| Alveolar bone density |
| 60 | Fixed | 0.18 | −0.33 to 0.69 | 0.48 | 0 | 0.40 | |
MD, mean difference; SMD, standardized mean difference; CI, confidence interval; PI, plaque index; PPD, probing pocket depth; CAL, clinical attachment level.
Intervention effect reported as SMD.